Asenapine Tablet
NDC Package 51991-358-11
Package Information
Asenapine (asenapine maleate) tablets is asenapine sublingual tablets are indicated for: Schizophrenia in adults [see Clinical Studies (14.1)] Bipolar I disorder [see Clinical Studies (14.2)]Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of ageAdjunctive treatment to lithium or valproate in adultsMaintenance monotherapy treatment in adults. This formulation utilizes a tablet delivery system. Marketed by Breckenridge Pharmaceutical, Inc., this product is identified by NDC 51991-358 and is authorized under FDA application ANDA205960.
Identification & Billing
- RxCUI: 1606337 - asenapine 2.5 MG Sublingual Tablet
- RxCUI: 1606337 - asenapine (as asenapine maleate) 2.5 MG Sublingual Tablet
- RxCUI: 859975 - asenapine 10 MG Sublingual Tablet
- RxCUI: 859975 - asenapine (as asenapine maleate) 10 MG Sublingual Tablet
- RxCUI: 859981 - asenapine 5 MG Sublingual Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51991 - Breckenridge Pharmaceutical, Inc.
- 51991-358 - Asenapine
- 51991-358-11 - 10 BLISTER PACK in 1 BOX / 10 TABLET in 1 BLISTER PACK (51991-358-99)
- 51991-358 - Asenapine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51991-358). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51991-358-11 identifies a specific commercial package of 10 blister pack in 1 box / 10 tablet in 1 blister pack (51991-358-99) of Asenapine, a human prescription drug labeled by Breckenridge Pharmaceutical, Inc.. This tablet is formulated for sublingual use and contains asenapine maleate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Breckenridge Pharmaceutical, Inc. on March 08, 2021. The current certification is valid through December 31, 2027.
How is this Breckenridge Pharmaceutical, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51991035811. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.